Skip to main content
. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207

Figure 1.

Figure 1

An algorithm for the treatment of relapse of AML after allogeneic hematopoietic stem cell transplant following a standard-of-care approach in the absence of an available clinical trial.